Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Erfonrilimab by Alphamab Oncology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According...
Erfonrilimab by Alphamab Oncology for Small-Cell Lung Cancer: Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...
Erfonrilimab by Alphamab Oncology for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
Erfonrilimab by Alphamab Oncology for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Erfonrilimab by Alphamab Oncology for Thymic Carcinoma: Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase...
Erfonrilimab by Alphamab Oncology for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Erfonrilimab by Alphamab Oncology for Gastric Cancer: Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
Erfonrilimab by Alphamab Oncology for Colorectal Cancer: Likelihood of Approval
Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...